

## Allergenfri luft i andningszonen nattetid

Christophe Pedroletti MD, PhD  
Verksamhetschef  
Pediatrik  
Akademiska Barnsjukhuset

### Bindningar och jäv


Publikation av de första två studierna på  
tekniken.

Ekonomiskt stöd för studierna från Airsonett  
Inga ekonomiska bindningar till den  
kommersialiserade produkten (aktier, patent,  
royalties)


Airsonett Advisory Board

Föreläsningssarvoden (Airsonett, AstraZeneca,  
Meda, GSK mfl).






## Konvektionströmmar och kroppsrörelser koncentrerar allergenen i andningszonen



## Partikelsimulering 5 $\mu\text{m}$

CFD simulation of particle concentrations around the breathing zone.




*Sigsgaard et al, manuscript in preparation*



## Partikelsimulering 20 $\mu\text{m}$


CFD simulation of particle concentrations around the breathing zone.




*Sigsgaard et al, manuscript in preparation*



## Flödessimulering (TLA)



## Den allergenfria hypotesen




## Astmatiker positiv effekt av TLA

Clinical effects of purified air administered to the breathing zone in allergic asthma: A double-blind randomized cross-over trial.


Pedroletti C et al, Respir Med. 2009

Nocturnal temperature controlled laminar airflow for treating atopic asthma: a randomised controlled trial. Boyle RJ et al

Thorax 2012



## Förbättrad livskvalitet och minskad bronkiell inflammation




Pedroletti et al  
Respir med 2009




## 4A STUDY – EUROPEAN MULTICENTER STUDY


Imperial College, London
University Hospital, Lund
County Hospital, Jönköping
Sahlgrenska, Gothenburg
County Hospital, Ängelholm
St Göran Hospital, Stockholm
Karolinska Hospital, Stockholm
Södersjukhuset, Stockholm
Allergimottagningen, Karlstad
University Hospital, Linköping
Children's Hospital, Munich
University Hospital, Rostock
Ruhr-Universität, Bochum
Marien Hospital, Wesel
Bispebjerg Hospital, Copenhagen
University Hospital, Aarhus
Terveystalo Allergy Centre, Turku
St Olav's Hospital, Trondheim




### Primary endpoint: AQLQ responders ( $\geq 0.5$ ) 1 year




### Secondary endpoint: Change in FENO, 1 year



### Sub group analysis: Change in FENO, 1 year




### Secondary endpoint: Relative change in specific IgE, 1 year





## Secondary endpoint: Relative change in specific IgE, 1 year




## Replik 1


TLA är inte en konventionell luftrenare  
 Våra subanalyser stöder hypotesen



- Astmasvårighetsgrad
- Multiallergi
- Exacerbationer



## Konventionella luftrenare




## TLA









## Replik 2

Svårt allergiska astmasjuka patienter  
behöver tillgång till behandlingen.

Endast skrivs ut av specialister på center

Vi behöver mer kunskap!

- Vem är den optimala patienten?
- Real-life data
- Nationellt vårdprogram
- Nationellt register